OCTN1¹¹ OCTN1
Organic Cation Transporter Novel 1 — a membrane transport protein expressed in the intestine, kidney, liver, lung, and immune cells that shuttles organic cations and the dietary antioxidant ergothioneine into cells is the product of the SLC22A4 gene on chromosome 5q31. The region around SLC22A4 is one of the earliest and most replicated inflammatory bowel disease susceptibility loci in human genetics — a 250 kb haplotype block called the IBD5 locus²² IBD5 locus
A linkage-disequilibrium block on chromosome 5q31 first identified in a Canadian sib-pair study of Crohn's disease; the locus spans SLC22A4, SLC22A5, and several immune-regulatory genes including IRF1 and IL5. The L503F missense variant in OCTN1 is one of two functional variants proposed to underlie the IBD5 risk haplotype, the other being rs2631367 (-207G>C) in the SLC22A5 (OCTN2) promoter.

The Mechanism

OCTN1 uses a sodium gradient to transport ergothioneine³³ ergothioneine
A naturally occurring amino acid synthesized only by fungi and some bacteria; humans obtain it entirely from diet, primarily through mushrooms, oats, and black beans; OCTN1 is the dedicated mammalian ergothioneine transporter into cells. The L503F substitution — a leucine-to-phenylalanine swap in the 11th transmembrane domain — meaningfully alters the transporter's kinetic profile.

Gründemann et al. showed⁴⁴ Gründemann et al. showed
PNAS 2009 — the 503F variant has 3-fold higher substrate affinity (lower Km) and 2-fold lower maximal transport velocity (Vmax) for ergothioneine, yielding 50% higher net transport efficiency at the physiological ergothioneine concentrations found in food and portal blood. The result: 503F carriers (CT and TT) accumulate higher ergothioneine concentrations in OCTN1-expressing tissues — including intestinal epithelium, macrophages, and neutrophils — than 503L homozygotes (CC) eating the same diet. In parallel, the 503F variant shows reduced carnitine transport (2.7-fold lower uptake) and altered uptake of various organic cations.

The functional paradox is that 503F is an ergothioneine gain-of-function variant associated with increased inflammatory disease risk. Current evidence suggests the primary causal signal at IBD5 may reside in nearby variants near IRF1 (Interferon Regulatory Factor 1)⁵⁵ Current evidence suggests the primary causal signal at IBD5 may reside in nearby variants near IRF1 (Interferon Regulatory Factor 1)
Festen et al., Nature Genetics 2011 — reanalysis of IBD5 suggested that 503F may be a recent European-enriched adaptation that swept to high frequency in linkage disequilibrium with the true causal signal, rather than being causal itself. Regardless of causality, the T allele remains a reliable risk tag for the IBD5 haplotype.

The Evidence

Peltekova et al.⁶⁶ Peltekova et al.
Nature Genetics 2004 — first proposed the two-locus IBD5 TC haplotype (SLC22A4 L503F-T + SLC22A5 -207C) as functional Crohn's disease risk variants; TC heterozygotes showed OR 2.1–2.56; TC/TC homozygotes showed OR 3.43–5.14 in two independent Canadian cohorts. This seminal finding made the IBD5 TC haplotype one of the best-replicated Crohn's disease susceptibility signals in the pre-GWAS era.

Subsequent replication studies confirmed the association in European cohorts. Noble et al., Gastroenterology 2005⁷⁷ Noble et al., Gastroenterology 2005
Studied TC haplotype in 1,400 Crohn's disease patients and 725 controls; TC/TC homozygotes were more likely to require intestinal resection and had higher rates of stricturing or penetrating disease, establishing a genotype-severity relationship beyond susceptibility alone.

Population data are striking: the T allele reaches 42% in European-Americans but drops to approximately 2% in East Asians, consistent with the observation that the IBD5 association with Crohn's disease is not observed in Japanese populations. This European enrichment has been proposed to reflect a recent selective sweep in European ancestry, possibly related to dietary adaptation to mushroom-rich environments.

Practical Actions

For TT homozygotes — carrying two copies of the 503F allele — the OCTN1 transporter accumulates particularly high ergothioneine tissue concentrations. The clinical significance is primarily as a tag for the IBD5 risk haplotype: elevated Crohn's disease susceptibility, with evidence that disease course may be more severe. Monitoring for early gastrointestinal symptoms and optimizing the gut microbiome through diet are the most actionable responses.

Because OCTN1 also regulates carnitine transport (with 503F reducing carnitine uptake 2.7-fold in vitro), TT homozygotes may have modestly reduced intestinal carnitine absorption. Carnitine status can be supported through dietary sources (red meat, dairy) or supplementation.

Interactions

The T allele at rs1050152 is the primary coding component of the IBD5 TC haplotype. Its partner variant, rs2631367 (-207G>C in the SLC22A5/OCTN2 promoter), reduces OCTN2 expression and synergizes with L503F to confer full TC haplotype risk for Crohn's disease. TC/TC homozygotes — those carrying the T allele here AND the C allele at rs2631367 — show the highest disease risk (OR 3.43–5.14) in the original Peltekova data. Single-locus carriage at either site confers intermediate risk.

Downstream of IBD5, NOD2/CARD15 variants (rs2066844, rs2066845, rs2066847) act in a common pathogenic pathway with the OCTN haplotype; compound carriage of IBD5 TC haplotype plus NOD2 variants may substantially further elevate Crohn's disease risk.

When a blood vessel wall becomes injured or inflamed, one of the body's first responders is the leukotriene pathway¹¹ leukotriene pathway
a branch of arachidonic acid metabolism that produces potent lipid-based inflammatory mediators from immune cells. ALOX5AP — arachidonate 5-lipoxygenase activating protein, also called FLAP (5-lipoxygenase activating protein) — is the essential scaffold protein that anchors the enzyme 5-lipoxygenase to the nuclear membrane, enabling it to convert arachidonic acid into leukotrienes. Without ALOX5AP, leukotriene biosynthesis essentially stops. Variants in ALOX5AP alter how much leukotriene the body makes when challenged by vascular stress, with downstream consequences for atherosclerosis, thrombosis, and stroke risk.

The Mechanism

rs10507391 is an intronic variant in ALOX5AP on chromosome 13q12 and is one of the four tagging SNPs that define the HapA haplotype²² HapA haplotype
a four-SNP risk haplotype in ALOX5AP first identified by deCODE Genetics in Iceland. The HapA haplotype is not a protein-coding change — it alters gene regulation and mRNA expression levels rather than the ALOX5AP protein sequence directly.

The A allele at rs10507391 has a cis-effect on ALOX5AP transcript levels and exerts trans-effects on expression of downstream pathway members ALOX5 and LTA4H in human aortic tissue samples with varying degrees of atherosclerosis. Crosslin et al., Human Genetics 2009³³ Crosslin et al., Human Genetics 2009 demonstrated that rs10507391 genotype significantly predicts expression across multiple leukotriene pathway nodes simultaneously — a signature of a regulatory hub variant influencing the entire biosynthetic axis.

The biological consequence: stimulated immune cells (neutrophils, monocytes) from A-allele carriers produce greater quantities of leukotriene B4 and cysteinyl leukotrienes. These are potent chemoattractants and vasoconstrictors that drive macrophage infiltration into atherosclerotic plaques, promote endothelial activation, and destabilize lipid cores — processes central to both plaque formation and acute thrombotic events.

The Evidence

The foundational study, Helgadottir et al., Nature Genetics 2004⁴⁴ Helgadottir et al., Nature Genetics 2004
deCODE Genetics, Iceland, identified the four-SNP ALOX5AP haplotype (HapA, which includes the rs10507391 A allele) as associated with approximately two-fold increased risk of myocardial infarction and stroke in an Icelandic population. Critically, the excess leukotriene B4 production in neutrophils was observed specifically in males carrying the at-risk haplotype, establishing a plausible sex-modulated biological mechanism.

Meta-analytic evidence for ischemic stroke has been mixed. A Caucasian-focused meta-analysis of 9 studies (4,198 cases, 3,699 controls)⁵⁵ Caucasian-focused meta-analysis of 9 studies (4,198 cases, 3,699 controls)
Li et al., Cell Mol Biol 2017 found significant association of rs10507391 with ischemic stroke risk (OR=1.18; 95% CI 1.08–1.28; P=0.0002), with the European subgroup showing OR=1.20. A larger, broader meta-analysis of 30 studies (32,782 participants)⁶⁶ broader meta-analysis of 30 studies (32,782 participants)
Zheng et al., Neuropsychiatr Dis Treat 2019 found no significant association overall (OR=1.03; 95% CI 0.93–1.14; P=0.557). This divergence likely reflects population stratification (the original Icelandic signal was ancestry-specific), haplotype-level effects not captured by single-SNP analysis, and interaction effects missed in pooled analyses.

The most mechanistically compelling validation comes from the European EUSTAR scleroderma cohort⁷⁷ European EUSTAR scleroderma cohort
Kowal-Bielecka et al., Rheumatology 2017 (977 SSc patients, 558 controls), where A-allele carriers at rs10507391 showed directly measured increases in cysteinyl leukotriene production from peripheral blood mononuclear cells. The variant associated with SSc susceptibility (OR=1.27; 95% CI 1.07–1.50) and, more strongly, with SSc-related interstitial lung disease (OR=1.45; 95% CI 1.17–1.79). This direct functional measurement of leukotriene excess provides mechanistic validation of the original Icelandic biological hypothesis.

A gene-gene interaction study in Chinese populations (Chi et al., Neuroreport 2014)⁸⁸ (Chi et al., Neuroreport 2014) found no individual effect of rs10507391 in isolation but a significant interaction with CYP3A5 A6986G that increased cerebral infarction risk nearly twofold (OR=1.80; 95% CI 1.18–2.76; P=0.006) — reinforcing the pattern that this variant's clinical impact depends heavily on genetic and environmental context.

Practical Actions

For AT heterozygotes, the primary action is monitoring inflammatory cardiovascular biomarkers — particularly high-sensitivity CRP, which integrates vascular inflammatory activity broadly and can motivate targeted lipid or anti-inflammatory therapy earlier than standard guidelines suggest.

For AA homozygotes, the evidence supports a more proactive approach: leukotriene-modulated inflammation is a distinct pathway from LDL-driven atherosclerosis, and conventional lipid management alone may not address it. Dietary shifts toward omega-3 fatty acids — specifically EPA (eicosapentaenoic acid), which competitively reduces leukotriene B4 synthesis — provide a mechanism-specific intervention. The 5-lipoxygenase pathway is also inhibited by flavonoids abundant in dark berries, quercetin-rich foods, and certain culinary herbs.

Smoking is particularly relevant here: smoking amplifies leukotriene production and synergizes with ALOX5AP genetic variation to increase atherosclerotic stroke risk in published interaction studies.

Interactions

rs10507391 is one of four tagging SNPs in the ALOX5AP HapA haplotype. The other HapA-defining SNPs (rs4769874, rs9551963, rs9315050, rs4147064) are all within ALOX5AP and collectively define the at-risk regulatory state — risk is maximal when multiple HapA alleles co-occur. HapA haplotype analysis consistently shows larger effects than any single tagging SNP analyzed alone.

A gene-gene interaction between rs10507391 and CYP3A5 rs776746 has been documented in cerebral infarction, with combined OR of ~1.80. CYP3A5 is involved in arachidonic acid metabolism, creating two-pathway convergence on leukotriene-mediated vascular inflammation. Individuals carrying risk alleles at both loci should be flagged for comprehensive cardiovascular inflammatory workup.

Pathway-level interactions with LTA4H (leukotriene A4 hydrolase, which converts the ALOX5AP product LTA4 into LTB4) and LTC4S (leukotriene C4 synthase, producing cysteinyl leukotrienes) have been documented — see related SNPs rs17222814 (LTA4H) and leukotriene receptor variants.

The glucocorticoid receptor encoded by NR3C1 is the cell's primary transducer of cortisol signaling — connecting the body's stress response to gene expression programs that regulate inflammation, metabolism, immune function, and cellular aging. Most NR3C1 variants studied to date alter GR sensitivity in ways that affect stress-related disease risk. This intronic variant (rs10515522) takes a different angle: it was discovered not through a disease study but through a longevity study, comparing the genomes of Polish nonagenarians and centenarians to those of newborn controls.

The signal is independent of the two other NR3C1 variants already catalogued in this database — rs6198 (9β)¹¹ rs6198 (9β), which alters GRβ isoform expression and blunts cortisol signaling, and rs41423247 (BclI)²² rs41423247 (BclI), which increases glucocorticoid sensitivity. rs10515522 sits in a different region of the gene and appears to exert its effect through a distinct mechanism, most likely regulatory rather than structural.

The Mechanism

rs10515522 is an intron variant at chromosome 5 position 143,378,829 (GRCh38). NR3C1 spans the minus strand of chromosome 5, so the T reference allele on the plus strand corresponds to an A on the coding strand, and the C alternate allele corresponds to a G. The variant has no known protein-coding consequence; its effect, if any, is likely on transcription regulation, splicing efficiency, or post-transcriptional processing of NR3C1 transcripts.

A 2018 haplotype study³³ 2018 haplotype study
Plieger T et al. NR3C1 and NR3C2 variation in cortisol response and cognition under acute stress. Psychoneuroendocrinology, 2017 included rs10515522 in a panel of 10 NR3C1 SNPs and found that the composite NR3C1 haplotype significantly predicted cortisol reactivity (p = 0.011) during acute stress challenge in 126 healthy males. rs10515522's contribution to the haplotype-level effect was not individually resolved, but its inclusion in the panel is consistent with the variant having regulatory influence on GR expression or activity.

The CC genotype's association with elevated total cholesterol⁴⁴ CC genotype's association with elevated total cholesterol
Olczak E et al., 2019 provides an additional functional clue: glucocorticoids directly regulate hepatic lipoprotein metabolism through GR-mediated transcription of cholesterogenic genes. Altered NR3C1 expression or splicing in liver tissue could plausibly shift the set point of glucocorticoid- driven cholesterol synthesis.

The Evidence

The primary evidence comes from a Polish centenarian cohort study. Olczak et al. (2019)⁵⁵ Olczak et al. (2019)
Glucocorticoid receptor gene polymorphisms are associated with age and blood parameters in Polish Caucasian nonagenarians and centenarians. Experimental Gerontology, 116:20-24 genotyped three NR3C1 variants (rs10515522, rs2963154, rs2918418) in 552 individuals aged 95-106 years from Polish Caucasian ancestry, compared against 284 cord blood samples from newborn controls.

Two findings are reported for rs10515522. In the cross-sectional comparison, the TT genotype was more prevalent in the long-lived group (p = 0.016) — a finding that must be interpreted carefully given that TT is simply the most common genotype overall (~71% European frequency). The more mechanistically informative finding is the survival analysis: carriers of the C minor allele (TC and CC combined, or possibly TC alone) had significantly better survival rates within the elderly cohort. This longitudinal signal — who survives longer after already reaching age 95 — is the stronger evidence of a longevity effect.

Additionally, the CC homozygous genotype was associated with elevated total cholesterol (p = 0.049), suggesting that two copies of the C allele shifts NR3C1 activity in a direction that affects hepatic lipid metabolism — a finding that echoes the effect also seen for rs2963154 in the same study.

The evidence level is emerging: this is a single cohort study with a moderate sample size. No independent replication of rs10515522's longevity association has been published. The biological mechanism remains speculative. However, the study's design — nonagenarians and centenarians are a gold-standard extreme-longevity phenotype — and its internal consistency across multiple NR3C1 variants give it more weight than a typical single-study finding.

Practical Implications

The longevity association of rs10515522 suggests that NR3C1 regulation in late life has measurable survival consequences. Given cortisol's central role in the biology of aging — mediating cellular senescence through glucocorticoid-driven atrophy of tissues including immune cells, hippocampal neurons, and skeletal muscle — variants that alter the GR's activity level or tissue-specific expression are plausibly relevant to healthspan and lifespan.

For TC carriers, the survival benefit observed in the centenarian cohort suggests that a single copy of the C allele may confer some advantage in maintaining GR-mediated adaptation into advanced age. For CC carriers, the cholesterol association introduces a clinically relevant consideration: lipid monitoring is warranted regardless of other risk factors, since altered GR activity in the liver may shift cholesterol metabolism independent of diet and lifestyle.

For TT carriers (the large majority), no specific longevity disadvantage is established by this single study, but the absence of the C allele means they don't share the survival benefit observed in the elderly cohort.

Interactions

rs10515522 operates within the same NR3C1 gene as rs6198 (9β)⁶⁶ rs6198 (9β) and rs41423247 (BclI)⁷⁷ rs41423247 (BclI). The three variants likely contribute to a composite NR3C1 haplotype that determines overall GR function. The haplotype study by Plieger et al. (2018) specifically examined rs10515522 alongside rs6198, rs41423247, and seven other NR3C1 SNPs, finding that the composite haplotype predicts cortisol reactivity more reliably than any single variant.

rs2963154, studied alongside rs10515522 in the longevity cohort, showed a similar but stronger effect (p = 0.002 for TT enrichment in centenarians) and associated with both total and HDL cholesterol. The two variants may tag the same or overlapping regulatory elements in the NR3C1 intron.

FKBP5 (rs1360780), a glucocorticoid receptor co-chaperone variant, would compound with any NR3C1 functional variant affecting HPA axis regulation, though no direct interaction data for rs10515522 specifically has been published.

Within a narrow region of chromosome 15 sits one of the most replicated genetic signals for smoking behavior ever discovered. The CHRNA3/CHRNA5/CHRNB4 gene cluster encodes three subunits of the nicotinic acetylcholine receptor (nAChR)—the molecular target of nicotine—and variants within it have been identified as the strongest genetic determinants of cigarette consumption, nicotine dependence, and smoking-related disease. rs1051730 is a synonymous variant in CHRNA3 (encoding no amino acid change at position 215) that nonetheless emerged from the largest smoking genetics consortium ever assembled¹¹ the largest smoking genetics consortium ever assembled
The TAG Consortium pooled over 74,000 participants and found rs1051730 to be the top signal for cigarettes per day at genome-wide significance: beta=1.03 cigarettes/day, p=2.8×10⁻⁷³ as the region's top marker for smoking quantity.

The variant does not change the CHRNA3 protein, but it sits in near-perfect linkage disequilibrium (LD)²² linkage disequilibrium (LD)
Two variants are in LD when they are so frequently inherited together that one effectively predicts the other; r²=1 means perfect co-inheritance in that population with rs16969968 in the neighboring CHRNA5 gene among people of European ancestry (r²≈1). In European populations, carrying the A allele at rs1051730 almost certainly means carrying the risk allele at rs16969968 as well—making it difficult to disentangle their individual contributions. However, because LD patterns differ across ancestral populations, rs1051730 and rs16969968 are not equivalent in all groups. In African Americans³³ African Americans
Two independent studies found rs1051730 associated with lung cancer risk (OR=1.59–1.81) in African Americans, where the variant may operate partly independently of rs16969968, the two variants show different frequencies and patterns of co-inheritance, making rs1051730 informative as a distinct signal.

The Mechanism

Because rs1051730 is synonymous, it does not directly alter the alpha-3 subunit's amino acid sequence. Its associated biological effects are thought to be primarily mediated through LD with rs16969968, which produces the Asp398Asn missense change in CHRNA5 and reduces alpha-5 nicotinic receptor function by approximately 50%. However, recent evidence suggests the region may also contain additional cis-regulatory variants⁴⁴ additional cis-regulatory variants
rs2036527 has been identified as an independent enhancer variant that regulates both CHRNA3 and CHRNA5 expression via chromatin looping, ChIP, and luciferase assays controlling gene expression levels of both CHRNA3 and CHRNA5, complicating the simple picture that rs16969968 alone explains all risk.

Nicotinic acetylcholine receptors containing the alpha-3 subunit are concentrated in the medial habenula, interpeduncular nucleus, and peripheral ganglia. These receptors govern two critical functions: the brain's aversive response to high nicotine doses (the natural brake on excessive smoking) and peripheral regulation of heart rate, lung function, and vascular tone. Reduced receptor function in this pathway weakens the signal that normally limits nicotine intake—allowing heavy smoking to develop without generating proportionally stronger aversion. The variant also modulates nicotine's effect on sensorimotor gating⁵⁵ modulates nicotine's effect on sensorimotor gating
In a controlled pharmacology study, TT homozygotes showed significant prepulse inhibition enhancement with nicotine while TC/CC carriers tended toward worsening—indicating genotype-dependent attentional responses to nicotine, a measure of attentional filtering relevant to attentional disorders and psychosis vulnerability.

The Evidence

The association with smoking quantity is among the most replicated findings in behavioral genetics. The TAG Consortium meta-analysis⁶⁶ TAG Consortium meta-analysis
Tobacco and Genetics Consortium pooled 74,053 European-ancestry participants from 16 genome-wide association studies found rs1051730[A] associated with approximately 1 extra cigarette per day per allele copy (beta=1.03, p=2.8×10⁻⁷³). Among heavy versus light smokers, the A allele confers OR≈1.34 (95% CI 1.21–1.49).

Lung disease risk is substantial and cumulative. A large population study of 57,657 Danes⁷⁷ large population study of 57,657 Danes
The Copenhagen General Population Study prospectively examined rs1051730 in 34,592 ever-smokers with spirometry and disease follow-up found that AA homozygotes had significantly reduced lung function (FEV₁ 94.1% predicted vs 96.5% in GG), a 70% higher risk of severe COPD (OR=1.7 for GOLD III-IV), and an 80% higher risk of lung cancer (OR=1.8) compared to GG noncarriers—a dose-dependent pattern where AG heterozygotes fell in between. These associations persisted after adjusting for cumulative tobacco consumption, suggesting effects beyond smoking quantity alone.

Lung cancer risk across diverse populations has been confirmed in multiple cohorts⁸⁸ multiple cohorts
A meta-analysis of 38 studies concluded that rs1051730 is associated with elevated lung cancer risk across Caucasian, African American, and Asian populations. Critically, in African Americans, where rs1051730 and rs16969968 are not in perfect LD, two independent studies found lung cancer ORs of 1.59–1.81⁹⁹ two independent studies found lung cancer ORs of 1.59–1.81
Amos et al. (OR=1.81, p=.001) and Schwartz et al. (OR=1.59, CI 1.16–2.19) both found significant lung cancer associations in African Americans; notably, these effects were "only weakly associated with smoking phenotypes," suggesting a direct carcinogenic pathway beyond nicotine behavior, with effects that were "only weakly associated with smoking phenotypes"—pointing to a potentially direct carcinogenic pathway beyond simply smoking more.

Cognitive effects have been documented but are modest. rs1051730 was among three CHRNA cluster SNPs¹⁰¹⁰ rs1051730 was among three CHRNA cluster SNPs
Among the WAIS-R cognitive battery, rs16969968 and rs1051730 were both associated with working memory performance on n-back tasks and the Continuous Performance Test in a European sample associated with working memory performance, verbal reasoning, and processing speed. This suggests the variant's effects on nicotinic signaling extend to everyday cognitive function, and may partly explain why nicotine acutely enhances attention in dependent smokers.

For smoking cessation, rs1051730 shows a weak association with short-term quit rates¹¹¹¹ a weak association with short-term quit rates
Meta-analysis of two UK clinical trials in treatment-seeking smokers found association at 4-week follow-up but not at longer intervals; effect was independent of NRT type and not explained by dependence severity alone. The effect appears modest and is not robust at longer follow-up intervals, suggesting the genotype is more relevant for understanding dependence than for predicting cessation success with current treatments.

Practical Actions

Carrying the A allele at rs1051730 signals elevated risk for developing heavy nicotine dependence and for smoking-related lung disease. In European-ancestry individuals, this is largely equivalent to carrying the CHRNA5 rs16969968 risk allele, and the practical guidance is similar: avoid initiating tobacco use, pursue intensive cessation support if smoking, and consider earlier lung cancer screening with adequate smoking history.

In individuals of African, South Asian, or Latino ancestry, rs1051730 may convey additional independent information beyond rs16969968, particularly for lung cancer risk. The population-stratified data suggest the variant's lung cancer association in African Americans may not be fully explained by smoking behavior, warranting vigilance even among lighter smokers or former smokers.

For patients with cognitive concerns or attention-related symptoms, understanding that nicotinic receptor genetics influences working memory and sensorimotor gating adds context—though no specific cognitive interventions are currently evidence-based for this genotype.

Interactions

In European-ancestry individuals, rs1051730 and rs16969968 (CHRNA5) are in near-perfect LD (r²≈1), meaning they almost always co-occur. They are effectively tagging the same haplotype, and carrying risk alleles at both positions simultaneously provides no additional independent risk assessment for Europeans. For non-European individuals, particularly those of African ancestry, the LD between the two variants is incomplete, making both variants informative as distinct signals.

The broader CHRNA5-CHRNA3-CHRNB4 cluster contains additional associated variants including rs578776, rs8034191 (AGPHD1), and rs6495309. The regulatory variant rs2036527 has been recently identified as a functional cis-eQTL controlling expression of both CHRNA3 and CHRNA5, and may partially explain associations attributed to rs1051730 through expression-level rather than coding-level mechanisms.

rs1051730's cognitive associations overlap with those of rs16969968 and may reflect the same underlying effect on nicotinic receptor function—weakening attention-modulating cholinergic signaling that normally supports working memory and sensory gating.

PPARδ¹¹ PPARδ
Peroxisome Proliferator-Activated Receptor delta — a nuclear receptor that coordinates gene expression programs for fatty acid oxidation, mitochondrial biogenesis, and muscle fiber-type switching in skeletal muscle is encoded by the PPARD gene on chromosome 6. The rs1053049 variant sits in the 3' untranslated region (3'UTR) of exon 9 — a regulatory stretch of RNA that is not translated into protein but profoundly influences how much PPARD mRNA is produced, how long it persists in the cell, and ultimately how much PPARδ protein is available to drive its downstream program.

This SNP is the third of three tag variants in the PPARD gene that together define a haplotype with striking consequences for elite athletic potential. Alongside rs2267668 (5' region) and rs2016520 (5'UTR, +294T>C), rs1053049 completes the A/C/C haplotype that has been studied in competitive athletes across multiple cohorts. It was identified as an independently significant marker for elite athletic status in its own right, with additional effects on skeletal muscle insulin sensitivity and body composition response to exercise.

The Mechanism

The 3'UTR is a post-transcriptional control hub. Variants in this region can disrupt or create microRNA binding sites²² microRNA binding sites
MicroRNAs are short non-coding RNAs that bind to complementary sequences in the 3'UTR of target mRNAs, triggering degradation or translational repression. A single 3'UTR SNP can abolish or create such a binding site, altering the amount of protein produced from an unchanged coding sequence, alter mRNA secondary structure affecting transcript stability, or modify polyadenylation signals that control mRNA half-life. While the precise molecular mechanism for rs1053049 has not been elucidated by in vitro reporter assays at the same level of detail as the rs2016520 promoter variant, the pattern of phenotypic associations — particularly the contrast between TT and TC genotypes for skeletal muscle glucose uptake — is consistent with a functional effect on PPARD expression levels in muscle tissue.

The key distinction from rs2016520 is anatomical: the 5'UTR variant (rs2016520) primarily affects transcriptional initiation through Sp-1 binding, while a 3'UTR variant like rs1053049 is more likely to influence post-transcriptional stability or translation efficiency. These mechanisms can have tissue-specific effects, which helps explain why the two variants show partially overlapping but distinct associations across metabolic, athletic, and body composition phenotypes.

The Evidence

The foundational study on rs1053049's metabolic significance was conducted by Vänttinen et al. at the University of Turku³³ Vänttinen et al. at the University of Turku
Vänttinen M et al. Single nucleotide polymorphisms in the peroxisome proliferator–activated receptor δ gene are associated with skeletal muscle glucose uptake. Diabetes, 2005. In 129 healthy subjects who underwent euglycemic hyperinsulinemic clamp procedures with PET imaging, the TC genotype of rs1053049 was significantly associated with higher whole-body and skeletal muscle glucose uptake compared with TT homozygotes (P = 0.028). This was a direct measurement of in vivo insulin sensitivity at the tissue level, not an association with a proxy marker, and it established that rs1053049 independently modulates how efficiently skeletal muscle takes up glucose in response to insulin.

A lifestyle intervention study using whole-body MRI⁴⁴ lifestyle intervention study using whole-body MRI
Thamer C et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 found that PPARD rs1053049 (along with rs6902123 and rs2267668) significantly affected the magnitude of lifestyle-intervention-induced changes in adiposity, hepatic fat storage, and relative muscle mass. Carriers of the minor C allele showed less reduction in adipose tissue mass (both nonvisceral and visceral, P = 0.02 and P = 0.01 respectively) and hepatic lipids (P = 0.04) in response to a structured diet and exercise program. This finding provides a mechanistic basis for why PPARD variation contributes to individual differences in body composition response to training and identifies rs1053049 as a predictor of whether lifestyle intervention will yield the expected adipose tissue reduction.

The landmark haplotype analysis of 660 elite athletes⁵⁵ haplotype analysis of 660 elite athletes
Maciejewska-Karlowska A et al. Genomic haplotype within the Peroxisome Proliferator-Activated Receptor Delta (PPARD) gene is associated with elite athletic status. Scand J Med Sci Sports, 2014 demonstrated that rs1053049 was individually associated with overall elite athletic performance (P = 0.0002) and specifically with strength-endurance sport athletes (P = 0.0003) when comparing 660 elite Polish athletes to 704 healthy controls. Crucially, the haplotype analysis showed that the complete A/C/C haplotype across all three PPARD variants (rs2267668-A / rs2016520-C / rs1053049-C) was dramatically underrepresented in every subgroup of elite athletes compared with controls (P < 0.000001). This is one of the strongest haplotype associations ever reported in sports genomics, and it establishes that the C allele at rs1053049 — in haplotype context with the other two variants — is associated with lower elite athletic potential.

A 12-week training intervention in 168 Polish women⁶⁶ 12-week training intervention in 168 Polish women
Leońska-Duniec A et al. The polymorphisms of the PPARD gene modify post-training body mass and biochemical parameter changes in women. PLOS One, 2018 found that TT homozygotes at rs1053049 were overrepresented in the group with higher post-training triglyceride levels. Haplotype analysis revealed that the G/C/C haplotype (rs2267668-G / rs2016520-C / rs1053049-C) was associated with post-training increases in fat-free mass and lower levels of cholesterol and triglycerides — suggesting that the broader haplotype context around rs1053049 determines whether the C allele is favorable or unfavorable for a given metabolic phenotype.

A 2023 Chinese military exerciser study⁷⁷ 2023 Chinese military exerciser study
Correlation between PPARD rs2267668 and rs1053049 polymorphisms with lower-limb strength in Chinese male exercisers. Mil Med Sci, 2023 found that the TT genotype of rs1053049 was significantly more common in the strong lower-limb strength group than in the weak group (64.7% vs 44.6%, P = 0.011), and the T allele frequency was higher in stronger exercisers (81.6% vs 66.2%, P = 0.004), supporting the idea that the T allele at this 3'UTR site confers an advantage for lower-body power output in trained individuals.

Practical Actions

The metabolic picture at rs1053049 is nuanced. TT homozygotes show higher skeletal muscle glucose uptake efficiency in response to strength training and may have an advantage for lower-limb power development. However, TT carriers also tend to show higher post-training triglyceride levels in some aerobic training contexts, suggesting that dietary fat quality and omega-3 supplementation are particularly relevant for TT individuals.

TC carriers show the highest measured insulin sensitivity in skeletal muscle (Vänttinen 2005 euglycemic clamp data) and may represent an intermediate metabolic phenotype. CC homozygotes appear to have reduced response to lifestyle-intervention-induced fat loss and are part of the haplotype most underrepresented in elite athletes, suggesting that the double-C genotype confers less favorable body composition adaptations to training.

Regardless of genotype, omega-3 fatty acids (EPA and DHA) are natural PPARδ ligands that directly activate the receptor protein — nutritionally amplifying the same fat-oxidation and metabolic programs that this variant affects at the gene expression level.

Interactions

rs1053049 is one of three PPARD haplotype tag SNPs; the others are rs2267668 (5' region) and rs2016520 (5'UTR +294T>C, already profiled separately). The full haplotype (rs2267668/rs2016520/rs1053049) is more predictive of elite athletic potential than any individual SNP, with the A/C/C haplotype showing p < 0.000001 for underrepresentation in elite athletes. Understanding your genotype at all three sites provides the most complete picture of your PPARD haplotype and its implications.

PPARGC1A rs8192678 (Gly482Ser), encoding PGC-1alpha — the transcriptional coactivator that physically partners with PPARδ to drive mitochondrial biogenesis — interacts powerfully with the PPARD locus as a whole. PPARD CC at rs2016520 combined with PPARGC1A Gly/Gly yields OR 8.32 for elite endurance status; the rs1053049 genotype adds further context to where an individual falls within this receptor-coactivator interaction.

Adiponectin is the most abundant hormone secreted by fat tissue, yet its effects run counter to what you might expect: despite originating in adipose cells, it works against the pathological consequences of excess fat. It sensitizes muscle and liver to insulin, suppresses inflammatory cytokines, and protects blood vessel walls from the calcification that drives atherosclerosis. Circulating adiponectin levels vary 10-fold between individuals, and much of that variation is genetic. The rs1063537 variant (+3228 C/T) sits at position 186,856,286 on chromosome 3 within the 3' untranslated region (3'UTR) of ADIPOQ — a stretch of RNA sequence that, while not coding for protein, acts as a control panel for mRNA stability and translational efficiency¹¹ control panel for mRNA stability and translational efficiency
the 3'UTR contains binding sites for RNA-binding proteins and microRNAs that regulate how much mRNA is degraded versus translated into protein; small sequence changes here can shift the steady-state amount of adiponectin protein produced by adipocytes.

The Mechanism

The ADIPOQ gene lies on the plus strand of chromosome 3 and its 3'UTR is a regulatory hub. Adipocytes express multiple microRNAs²² microRNAs
small non-coding RNA molecules that bind to the 3'UTR of target mRNAs and typically reduce their translation or promote their degradation that target ADIPOQ mRNA, including miR-378 and miR-221. A C-to-T change at the +3228 position alters the local RNA secondary structure and microRNA binding affinity, modulating how quickly the transcript is cleared. The net result: C allele carriers have lower average circulating adiponectin than T allele carriers. In the Chingford cohort³³ In the Chingford cohort
Kyriakou et al. 2008, two female cohorts totalling >2,400 women, TT homozygotes had mean fasting adiponectin of 24.87 μg/mL versus 19.90 μg/mL in CC homozygotes — a 25% difference driven by a single nucleotide change in an untranslated region.

The C allele at rs1063537 is the GRCh38 reference allele and is far more common globally (~79% CC genotype, ~12% T allele frequency in Europeans, ~28% in East Asians). Because the common allele is the one that reduces adiponectin, the majority of the population operates at a mild adiponectin disadvantage relative to the rare T homozygotes.

The Evidence

Fasting adiponectin levels: The clearest functional signal for rs1063537 comes from Kyriakou et al. 2008⁴⁴ Kyriakou et al. 2008
Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity. J Hum Genet. 2008, which showed additive association (p=0.01) with serum adiponectin in 800 UK women, where each T allele added approximately 2–2.5 μg/mL to circulating levels. This replication in a second cohort of 1,629 women was not significant, suggesting a modest effect that requires large samples.

Type 2 diabetes: A Han Chinese case-control study of 768 subjects by Chung et al.⁵⁵ Chung et al.
Association of four insulin resistance genes with type 2 diabetes mellitus and hypertension in the Chinese Han population. Mol Biol Rep. 2014 found the T allele was protective against T2DM: allele frequency was 26.8% in T2DM cases versus 36.3% in controls (OR=0.64, 95% CI 0.45–0.91, p=0.014). This is consistent with the T allele's association with higher adiponectin, which enhances insulin sensitivity.

Coronary artery calcification: In the Multi-Ethnic Study of Atherosclerosis (MESA)⁶⁶ Multi-Ethnic Study of Atherosclerosis (MESA)
Associations of SNPs in ADIPOQ and subclinical cardiovascular disease. Atherosclerosis. 2012 — 712 African American participants — the AG/AA genotypes of rs1063537 (note: the study used a complementary notation for the same variant; the C allele corresponds to the major G in that encoding) were associated with a 35% greater coronary artery calcification (CAC) prevalence (PR=1.35–1.39, p=0.0005). This finding did not replicate in non-African ancestry groups, and rs1063537 was in high LD with the neighboring rs1063539 (r²=0.90 in African Americans), suggesting the signal may tag a haplotype specific to African ancestral populations.

Diabetic nephropathy: A Taiwanese longitudinal study by Lin et al. 2014⁷⁷ Lin et al. 2014
Adiponectin gene (ADIPOQ) polymorphisms correlate with the progression of nephropathy in Taiwanese male patients with type 2 diabetes. Diabetes Res Clin Pract. 2014 followed 566 T2DM patients with normoalbuminuria over six years. Males carrying the CC genotype had HR=1.89 for nephropathy progression (vs CT+TT, 95% CI 1.15–3.11, p=0.013). A more recent study of 538 Chinese Han T2DM patients found TT genotype carriers had a 2.47-fold higher risk of macroalbuminuria versus CC (p=0.016) — an apparently paradoxical finding that may reflect the nonlinear biology of adiponectin in established kidney disease, where adiponectin's anti-inflammatory signaling in the renal cortex may be altered by chronic inflammation.

Obstructive sleep apnea: Chen et al. 2019⁸⁸ Chen et al. 2019
ADIPOQ rs1063537 and obstructive sleep apnoea in Chinese Han adults. Targeted sequencing. OMICS. 2019 found CT/TT genotypes associated with 2.155-fold increased OSA risk (95% CI 1.149–4.041, p=0.017), with significantly higher apnea-hypopnea index (23.20 vs 17.15 events/hour, p=0.004). The mechanism may involve adiponectin's modulation of upper airway muscle tone and inflammation, though this finding requires replication.

Practical Implications

Low circulating adiponectin is a well-established driver of insulin resistance and cardiometabolic risk. For CC carriers, the primary levers are lifestyle factors known to upregulate ADIPOQ transcription and secretion: omega-3 fatty acids activate PPARγ⁹⁹ PPARγ
peroxisome proliferator-activated receptor gamma — the master regulator of adipocyte gene expression that directly drives ADIPOQ transcription, weight loss disproportionately raises adiponectin relative to other adipokines, and moderate caloric restriction upregulates adiponectin secretion. Monitoring fasting insulin and HOMA-IR provides a functional readout of whether adiponectin signaling is adequate.

For individuals with established T2DM, regular monitoring of urine albumin-to-creatinine ratio (uACR) is warranted given the nephropathy progression risk documented in this population — particularly in males, where the sex-specific HR=1.89 signal was found.

Interactions

rs1063537 lies at the 3' end of ADIPOQ within a block of variants that includes rs1063539 (high LD in African Americans, r²=0.90). The larger ADIPOQ haplotype context is defined by rs17300539 (−11391G>A promoter), rs182052 (−10066A>G intron), rs2241766 (+45T>G exon 2), and rs1501299 (+276G>T intron 2) — all already profiled in GeneOps. Together these variants define six common ADIPOQ haplotypes that explain substantially more variance in circulating adiponectin than any single SNP alone. Individuals carrying the CC genotype at rs1063537 plus the risk alleles at rs2241766 (G) and rs182052 (A) may face compounded reduction in adiponectin output via convergent transcriptional, post-transcriptional, and translational mechanisms.

Basonuclin-2 (BNC2) is a zinc finger transcription factor expressed during skeletal development with roles in regulating cell proliferation and differentiation in growth plate cartilage and intervertebral disc tissue. rs10738445 sits in intron 3 of BNC2¹¹ rs10738445 sits in intron 3 of BNC2
an intronic position at chr9:16,680,140 (GRCh38) within a transcriptional enhancer region, not in a protein-coding exon. Despite its non-coding location, this variant exerts a measurable functional effect on gene expression — and that shift in expression is what links it to adolescent idiopathic scoliosis²² adolescent idiopathic scoliosis
AIS — abnormal lateral curvature of the spine developing during the adolescent growth spurt, affecting approximately 2–3% of adolescents worldwide.

AIS is the most common pediatric spinal disorder. Most cases are mild, but roughly 10% of affected individuals develop curves severe enough to require bracing or surgery. The genetic architecture of AIS is complex and polygenic, with rs10738445 being one of the most consistently replicated susceptibility loci — validated across Japanese, Chinese, European, and multi-ethnic international cohorts.

The Mechanism

The C allele at rs10738445 creates an allele-specific transcription factor binding site³³ allele-specific transcription factor binding site
demonstrated by electrophoretic mobility shift assay (EMSA): the C allele binds the transcription factor YY1 approximately 1.3-fold more strongly than the A allele. YY1 (Yin Yang 1) is a ubiquitous zinc finger transcription factor that activates or represses genes depending on cellular context. At this locus, stronger YY1 binding drives higher BNC2 enhancer activity, elevating BNC2 mRNA levels in relevant tissues.

When BNC2 was overexpressed in zebrafish, the animals developed body curvature in a gene-dosage-dependent manner — direct experimental evidence that elevated BNC2 is sufficient to cause a scoliosis-like phenotype in a vertebrate model. In human AIS patients, BNC2 expression in spinal tissue is significantly higher than in controls, and expression magnitude correlates with curve severity (r=0.316, p=0.02), establishing a dose-response relationship between BNC2 expression and disease severity⁴⁴ establishing a dose-response relationship between BNC2 expression and disease severity
Xu et al. 2017, Chinese cohort of 2,645 patients and 2,746 controls.

The intersection with inflammatory pathways is less well characterised, but BNC2 expression is regulated by pro-inflammatory cytokines in growth plate and disc tissue. This may explain, in part, why AIS progression correlates with inflammatory markers and why this variant is catalogued in the innate immunity depth panel.

The Evidence

The discovery study by Ogura et al. 2015⁵⁵ Ogura et al. 2015
"A Functional SNP in BNC2 Is Associated with Adolescent Idiopathic Scoliosis", American Journal of Human Genetics, 2015 identified rs10738445 through GWAS followed by functional validation in 2,109 AIS cases and 11,140 controls from Japanese and Chinese populations. The C allele showed OR=1.21 (p=2.46×10⁻¹³) for AIS susceptibility. This was independently replicated in a Chinese cohort⁶⁶ a Chinese cohort
Xu et al., Molecular Genetics and Genomics, 2017 with 2,645 patients and 2,746 controls (OR=1.14–1.24), and confirmed in an international meta-analysis of 8,756 cases and 27,822 controls⁷⁷ international meta-analysis of 8,756 cases and 27,822 controls
Ogura et al., Scientific Reports, 2018 spanning seven ethnicities (using the linked proxy rs3904778, combined p=3.28×10⁻¹⁸, OR=1.19, 95% CI 1.14–1.24).

The most clinically actionable finding comes from Dai et al. 2025⁸⁸ Dai et al. 2025
"Genetic Variants Can Predict the Outcome of Brace Treatment in Patients With Adolescent Idiopathic Scoliosis", Spine, 2025. In 259 female AIS patients undergoing brace treatment, the C allele was the only significant predictor of treatment failure among five candidate SNPs tested (OR=1.59), with 30.5% of patients experiencing curve progression exceeding 5 degrees. This positions rs10738445 as a potential clinical decision-support marker for predicting which adolescents are likely to fail conservative bracing therapy.

Notably, the BNC2 locus association is specific to adolescent-onset disease: a Japanese cohort study⁹⁹ Japanese cohort study
Takeda et al. 2019 found no significant association with adult spinal deformity, indicating the variant operates through mechanisms tied to growth-phase skeletal development.

Practical Actions

For carriers of the C allele who are parents of adolescents, or who are in the adolescent growth phase themselves, the main implication is heightened awareness: AIS typically develops during the rapid growth spurt (ages 10–15 in girls, 12–16 in boys) and is most successfully treated when detected early. Screening by a paediatric orthopaedist during this window allows intervention before curves progress beyond the bracing threshold (Cobb angle 25–45°).

For adolescents already diagnosed with AIS and undergoing bracing, the Dai 2025 data suggest that C/C homozygotes face a meaningfully higher risk of brace failure (OR=1.59 per allele). This does not mean bracing should be abandoned — it remains first-line treatment — but it justifies closer radiographic monitoring intervals and earlier consideration of surgical consultation if curve progression occurs despite compliant brace use.

Interactions

rs10738445 lies approximately 1.8 kb from rs3904778, the proxy SNP used in most international GWAS and the meta-analysis by Ogura 2018. Both variants tag the same BNC2 locus; rs10738445 has been specifically validated as the functional variant through enhancer assay and YY1 binding experiments, while rs3904778 is the more widely studied GWAS tag. Carriers may have both SNPs genotyped — the two track closely but are not in perfect LD across all populations.

AIS susceptibility is polygenic. Other replicated loci include SOX9/KCNJ2 (rs12946942), TBX1 (rs1978060), and CHD7 (rs1017861). The Dai 2025 study examined these alongside rs10738445 and found only rs10738445 significantly predicted bracing outcome, suggesting it may capture a biologically distinct component of AIS pathogenesis related to the progression-relevant enhancer activity of BNC2.

Nucleobindin-2 (NUCB2) on chromosome 11p15.1 encodes the precursor protein for nesfatin-1¹¹ nesfatin-1
An 82-amino acid neuropeptide cleaved from NUCB2 that suppresses appetite and modulates insulin secretion via melanocortin MC3/MC4 receptors and CRF2 — functions leptin-independently, so it retains activity even in obesity where leptin resistance has developed, a neuropeptide governing appetite, glucose regulation, blood pressure, and sleep-wake cycling. The rs10766383 variant sits deep within an intron of NUCB2 (GRCh38 chr11:17308251), close to other studied NUCB2 intronic and coding variants — rs1330 and rs214101 — that have been linked to overlapping metabolic and oncological phenotypes. Like its neighbours, rs10766383 does not alter the nesfatin-1 amino acid sequence; its effects are thought to be regulatory, influencing NUCB2 transcript levels, splicing efficiency, or local chromatin accessibility.

The T allele is the minor allele globally (~25%) but reaches ~50% frequency in East Asian populations, explaining why its T2DM association was first detected in a Chinese Han cohort. The G allele is the GRCh38 reference and represents the common, wild-type NUCB2 expression state. This is a straightforward CLEAN pattern: GG carries the lowest genetic risk at this locus.

The Mechanism

As a deep intron variant, rs10766383 does not produce a protein-level change. Its regulatory mechanism is inferred from population-level associations and from what is known about how NUCB2 intronic variants affect gene expression. Possibilities include altered binding of transcription factors or RNA-binding proteins within an intronic regulatory element, changes in alternative splicing efficiency across NUCB2's multiple transcript isoforms, or effects on local histone modification patterns that alter promoter accessibility. Any of these would reduce the amount of NUCB2 protein available for proteolytic processing into nesfatin-1.

Reduced circulating nesfatin-1 is a consistent finding in obesity, insulin-resistant states, and several cancers — suggesting that an intronic variant that lowers NUCB2 expression could compound both metabolic and oncological vulnerability through a single mechanism of nesfatin-1 insufficiency. The sex-specific pattern of T2DM association (significant only in females in the Li 2020 cohort) mirrors the pattern seen at rs1330 in the same study and likely reflects estrogen-dependent modulation of NUCB2 transcription in hypothalamic and pancreatic circuits.

The Evidence

Type 2 diabetes. Li et al. (2020)²² Li et al. (2020)
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 genotyped 578 T2DM patients against 1,609 healthy controls in a Chinese Han population. rs10766383 was one of four NUCB2 SNPs significantly associated with T2DM overall (T allele OR 1.29, 95% CI 1.12–1.47, P=0.0003). In sex-stratified analysis, the association was statistically significant only in females (OR 1.32, 95% CI 1.03–1.68, P=0.027) and did not reach significance in males (P=0.096). The T allele frequency in cases was 47.8% vs 41.6% in controls. No significant BMI association was detected at this specific locus, unlike rs1330 which did show BMI effects.

Oral cancer progression. Yu et al. (2026)³³ Yu et al. (2026)
Yu CC et al. Association of NUCB2 genetic variants with the clinicopathological features of oral cancer. 2026 examined four NUCB2 SNPs in 1,161 Taiwanese male oral cancer patients and 1,186 healthy controls. rs10766383 TG/GG genotypes (T as the analyzed allele here) were not associated with overall oral cancer susceptibility after lifestyle-factor adjustment. However, in patients aged ≥60 years, carrying TG or GG genotypes (at least one T allele) was associated with significantly higher risk of advanced-stage (III/IV) disease (OR 1.748, 95% CI 1.160–2.632) and lymph node metastasis (OR 1.963, 95% CI 1.207–3.194). The pattern was consistent with the other three NUCB2 SNPs studied, all showing associations with progression rather than susceptibility — supporting the hypothesis that reduced nesfatin-1 activity impairs anti-tumor immune surveillance or directly promotes tumor invasiveness in older patients.

Nesfatin-1 and cancer biology. A 2021 review by Kmiecik et al.⁴⁴ Kmiecik et al.
Kmiecik AM et al. Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule? Int J Mol Sci, 2021 synthesized evidence that nesfatin-1 exhibits anti-proliferative and pro-apoptotic effects in colorectal, hepatocellular, and other cancer cell lines. Reduced serum nesfatin-1 has been documented in multiple cancer contexts, suggesting a tumor-suppressive function that nesfatin-1 deficiency (from either obesity or genetic factors reducing NUCB2 expression) may undermine.

Sleep biology. rs10766383 has not been studied directly in sleep research, but NUCB2/nesfatin-1 has an established role in sleep-wake regulation. Vas et al. (2013, PLoS One)⁵⁵ Vas et al. (2013, PLoS One)
Vas S et al. Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS One, 2013 showed that central nesfatin-1 reduces REM sleep and increases wakefulness in rats, and that hypothalamic NUCB2 expression rebounds during sleep recovery after deprivation. Intronic variants reducing NUCB2 output may therefore affect sleep architecture at the population level, though direct human data at rs10766383 are lacking.

Practical Implications

The T2DM association is female-specific and of moderate effect size (OR ~1.3). The most actionable implication is metabolic monitoring in female T carriers — fasting glucose and insulin resistance markers are the appropriate early warning signals. For the oral cancer finding, the association applies to older patients already diagnosed (progression risk), not susceptibility, so oncological surveillance context is the practical frame for GT/TT carriers, particularly males over 60.

Interactions

rs10766383 was studied alongside rs1330, rs214101, and rs757081 in both the Li 2020 T2DM and Yu 2026 oral cancer papers. All four NUCB2 variants showed broadly consistent directions of effect — T2DM risk (Li 2020) and oral cancer progression risk (Yu 2026) — suggesting they may act as a haplotype or collectively reduce NUCB2/nesfatin-1 output through complementary regulatory and protein-level mechanisms. Individuals carrying risk alleles at multiple NUCB2 loci may experience compounded nesfatin-1 insufficiency beyond what any single variant predicts.

Most people who know about BDNF (brain-derived neurotrophic factor) know it as the brain's plasticity hormone — the factor that strengthens memories, supports neuroplasticity, and responds to exercise. That well-known story belongs to rs6265 (Val66Met), a coding variant that affects BDNF secretion in neurons and is covered in the Brain & Mental Health section of this encyclopedia.

This variant — rs10767664 — tells a different story entirely. It sits in intron 3 of the BDNF gene, within a conserved enhancer region called BE5.1¹¹ conserved enhancer region called BE5.1
A 494 base pair stretch of DNA that has been preserved across vertebrate evolution for over 360 million years, suggesting a critical biological function. It controls BDNF expression specifically in hypothalamic cells, and it affects BDNF's role not in learning and memory but in hypothalamic satiety signaling²² hypothalamic satiety signaling
The process by which the hypothalamus receives signals from the body that food intake is sufficient and suppresses appetite. BDNF in the ventromedial hypothalamus is a critical relay in this satiety circuit. This variant was identified in one of the largest genome-wide association studies of body mass index ever conducted, affecting approximately 250,000 individuals, and the association is among the strongest ever found for obesity.

The Mechanism

BDNF is highly expressed in the ventromedial hypothalamus (VMH)³³ ventromedial hypothalamus (VMH)
The region of the hypothalamus primarily responsible for satiety. Neurons here receive leptin signals and fire to suppress appetite. When BDNF signaling in the VMH is reduced, animals overeat and gain weight, where it functions as a critical downstream effector of the melanocortin-4 receptor (MC4R) pathway⁴⁴ melanocortin-4 receptor (MC4R) pathway
MC4R is activated by alpha-MSH, a hormone produced when leptin signals "enough food." MC4R activation upregulates BDNF in the VMH, which then sustains the satiety signal. This is why MC4R and BDNF variants both appear as top obesity GWAS hits — they are in the same molecular pathway. When you eat and leptin rises, MC4R activation stimulates BDNF expression in VMH neurons⁵⁵ stimulates BDNF expression in VMH neurons
Xu B et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nature Neuroscience, 2003, and that BDNF signal then propagates satiety through TrkB receptors, suppressing further food intake.

The rs10767664 A allele disrupts this process at the source. Research in primary hypothalamic cells shows that the T allele (the protective minor allele) functions as an active enhancer of BDNF promoter 4 — driving BDNF transcription in response to neuronal signals. The A allele, which is actually the more common version, fails to enhance promoter activity. The result: reduced BDNF expression in the hypothalamus, weaker satiety signaling after meals, and a sustained drive to keep eating.

Recent research further refined this picture by showing that astrocytes in the VMH⁶⁶ astrocytes in the VMH
Non-neuronal support cells that regulate synaptic communication. VMH astrocytes express TrkB.T1 (a truncated BDNF receptor) and use BDNF signaling to modulate neuronal activity in response to energy state also require intact BDNF/TrkB signaling⁷⁷ require intact BDNF/TrkB signaling
Ameroso et al. Astrocytic BDNF signaling within the ventromedial hypothalamus regulates energy homeostasis. Nature Metabolism, 2022 for normal energy homeostasis. Mice lacking TrkB.T1 in VMH astrocytes develop increased body weight, leptin resistance, and impaired glucose tolerance — a metabolic syndrome profile strikingly similar to what rs10767664 A homozygotes are at risk for.

The Evidence

The GIANT consortium meta-analysis⁸⁸ GIANT consortium meta-analysis
Speliotes EK et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010 of 249,796 individuals identified the BDNF locus as one of 18 new BMI- associated signals, with rs10767664 reaching p = 5 × 10⁻²⁶ — far beyond the genome-wide significance threshold. Each copy of the A allele increases BMI by an estimated 0.19 kg/m² (95% CI 0.13–0.25), placing the BDNF locus among the strongest obesity GWAS hits identified. The effect was confirmed in a diverse-ancestry replication cohort.

Human feeding data confirms the mechanistic prediction. In the Look AHEAD Trial⁹⁹ Look AHEAD Trial
A large NIH-funded trial studying lifestyle intervention for overweight adults with type 2 diabetes, n=5,145, carriers of the AA genotype consumed over 100 kcal per day more¹⁰¹⁰ carriers of the AA genotype consumed over 100 kcal per day more
McCaffery et al. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. Am J Clin Nutr, 2012 than carriers of the T allele (p = 0.006), and this effect persisted after adjusting for body weight — confirming it reflects an appetite difference, not just a consequence of greater body mass.

The metabolic consequences extend beyond weight. In a prospective study of 507 obese Caucasian women, T allele carriers faced 1.33-fold higher odds of type 2 diabetes¹¹¹¹ T allele carriers faced 1.33-fold higher odds of type 2 diabetes
de Luis DA et al. rs10767664 gene variant in BDNF is associated with diabetes mellitus type 2 in Caucasian females with obesity. Ann Nutr Metab, 2017 (95% CI 1.17–2.08) compared to non-carriers, with higher BMI, waist circumference, fasting glucose, HOMA-IR, insulin, and CRP in the T-carrier diabetic subgroup. A separate intervention study in 80 obese patients on a calorie-restricted diet found AA homozygotes lost significantly more weight¹²¹² AA homozygotes lost significantly more weight
de Luis DA et al. RS 10767664 gene variant in brain derived neurotrophic factor (BDNF) affect metabolic changes and insulin resistance after a standard hypocaloric diet. J Diabetes Complications, 2018 (3.4 vs 1.7 kg, p=0.01) with better fat mass reduction, triglyceride improvement, and insulin sensitivity gains than T carriers, suggesting T allele carriers may have a complex metabolic phenotype with worse insulin resistance independent of current weight.

Practical Implications

The A risk allele is very common — roughly 63% of people of European descent are AA homozygotes and another 32% are AT heterozygotes. Carrying the risk allele does not mean inevitable obesity; it means your hypothalamic satiety brake at this locus is less powerful than in the uncommon TT genotype. The 100 kcal/day difference in intake observed in the Look AHEAD trial is modest in isolation, but accumulated over months and years — and compounded with other obesity-risk loci — it represents a genuine appetite disadvantage worth counteracting proactively.

The most genotype-specific intervention follows directly from the mechanism: strategies that enhance post-meal satiety signaling (protein-first eating, high-fiber meal starters, time-structured eating) can compensate for reduced hypothalamic BDNF tone. For AA and AT carriers with metabolic concerns, monitoring fasting insulin and HOMA-IR provides an early warning signal for insulin resistance that this genotype predisposes to.

Interactions

rs10767664 and MC4R (rs17782313) are in the same satiety signaling cascade. BDNF is a downstream effector of MC4R in the VMH, meaning both proteins must function for full satiety signal propagation. A carrier of both the MC4R risk allele (rs17782313 C) and the BDNF obesity allele (rs10767664 A) has impairment at two consecutive steps in the same hypothalamic circuit, creating a compounded appetite dysregulation greater than either variant alone. Specific interaction studies at the genotype level have not been published, but the shared mechanistic pathway provides a strong biological rationale.

FTO (rs9939609) and rs10767664 operate through independent mechanisms — FTO primarily affects thermogenesis and adipogenesis through IRX3/IRX5 in brown fat and hypothalamus, while rs10767664 acts on VMH satiety signaling via the BDNF-TrkB pathway. Their BMI effects are additive rather than synergistic. Large-scale polygenic risk score analyses confirm that carrying risk alleles at both loci produces meaningfully higher obesity risk than either alone.

This variant is distinct from rs6265 (BDNF Val66Met), which is catalogued in the Brain & Mental Health section. rs6265 is a missense variant in the BDNF coding sequence that impairs activity-dependent BDNF secretion from neurons, affecting memory and neuroplasticity. rs10767664 is a regulatory variant that reduces BDNF expression in the hypothalamus, affecting satiety signaling and energy balance. The two variants show weak linkage disequilibrium and can be inherited independently — a person may carry one, both, or neither risk allele.

Your immune system uses antibodies as molecular flags — tagging pathogens and cellular debris for removal. The actual removal work is done by macrophages, neutrophils, and dendritic cells carrying a surface receptor called FcγRIIa, encoded by FCGR2A. This receptor is the cell's sensor for IgG antibody complexes: when an immune complex¹¹ immune complex
A cluster of antigens bound by multiple IgG antibodies, forming a molecular aggregate that signals phagocytes to engulf and destroy the target lands on a macrophage's FcγRIIa receptor, the cell ingests and destroys it. rs10800309 sits in a regulatory region of FCGR2A that controls how many of these receptors appear on the cell surface — influencing the immune system's overall capacity to clear immune complexes before they accumulate in tissues and trigger inflammation.

When immune complex clearance is impaired — whether through reduced receptor affinity (the well-studied rs1801274 H131R variant) or through reduced receptor quantity (the mechanism implicated by rs10800309) — immune complexes can deposit in the kidneys, joints, and small vessels, triggering the complement cascade and the chronic inflammation that characterizes diseases like lupus nephritis and rheumatoid arthritis.

The Mechanism

rs10800309 is located approximately 3.1 kilobases upstream of the FCGR2A transcription start site, within a region identified by CRISPR-based regulatory mapping²² CRISPR-based regulatory mapping
Researchers used CRISPR interference (CRISPRi) to systematically silence 1.7 Mb of open chromatin around FCGR2A, identifying upstream subregions that reduce transcript levels when silenced as harboring important enhancer activity for FCGR2A expression in myeloid cells. It forms a tight [haplotype block | A haplotype block is a chromosomal region where alleles co-segregate due to limited historical recombination; variants in the same block often tag the same underlying functional change] with rs4657039 and rs6696854, suggesting that all three variants together mark the same functional change in the upstream regulatory region.

The A allele at rs10800309 is associated with higher FcγRIIa surface expression on myeloid cells including dendritic cells and monocytes. Carriers of the AA genotype show statistically increased receptor density, while GG homozygotes show the lowest expression. This is consistent with the variant acting as an expression quantitative trait locus (eQTL)³³ expression quantitative trait locus (eQTL)
An eQTL is a DNA variant that predicts how much of a gene product is made — not what the protein looks like, but how many copies are produced for FCGR2A in immune cells. The downstream consequence is quantitative: fewer receptors means slower, less efficient capture and clearance of IgG immune complexes.

The Evidence

The most direct evidence for rs10800309's functional importance comes from a cohort study of HIV controllers⁴⁴ cohort study of HIV controllers
251 HIV controllers vs 250 HIV progressors from predominantly Caucasian cohorts; controller status defined as viral load below 400 copies/mL without antiretroviral therapy (Roederer et al., Genes & Immunity, 2020) that genotyped five FCGR2A SNPs in 501 participants. The AA genotype of rs10800309 was associated with natural HIV-1 control with an odds ratio of 2.84 (95% CI 1.20–6.89, P=0.033) even after adjusting for HLA-B57 and HLA-B27 — the dominant genetic determinants of HIV control. Crucially, the same AA genotype was independently confirmed to predict increased FcγRIIa surface expression on myeloid dendritic cells in a flow cytometry experiment (P=0.0032), establishing that the genotype operates through receptor quantity, not receptor structure.

In the context of autoimmune disease, rs10800309 was investigated as part of a five-SNP FCGR2A haplotype study⁵⁵ five-SNP FCGR2A haplotype study
422 UC patients and 710 healthy controls from southeastern China; haplotype analysis using PHASE software in ulcerative colitis. While the individual genotype frequencies of rs10800309 did not reach significance between patients and controls, the haplotype block it anchors (rs4657039-rs6696854-rs10800309) is an independently inherited segment that collectively influences FCGR2A expression. Separately, the FCGR2A locus — including the broader region containing this haplotype block — has been replicated as an ulcerative colitis susceptibility locus⁶⁶ ulcerative colitis susceptibility locus
GWAS-identified locus with genome-wide significant p-values in Japanese and Korean IBD cohorts.

The biological mechanism linking reduced FcγRIIa expression to autoimmunity is well-established through work on the companion missense variant rs1801274. Individuals with lower-functioning FcγRIIa fail to efficiently clear IgG-opsonized immune complexes; these complexes accumulate in tissues, activate complement, and drive the chronic inflammation underlying lupus nephritis, rheumatoid arthritis, and inflammatory bowel disease. The rs10800309 expression-level effect operates in parallel to this receptor-function effect — compounding risk when the G allele co-occurs with the R131 (G allele of rs1801274) functional variant.

Practical Actions

The GG genotype at rs10800309 reflects reduced FcγRIIa receptor quantity on myeloid cells. For most people, this is a background predisposition rather than a deterministic disease signal — particularly if the companion rs1801274 genotype indicates adequate receptor affinity. The most evidence-backed strategies target the downstream consequences of suboptimal immune complex clearance: supporting immune resolution through long-chain omega-3 fatty acids and vitamin D, and monitoring for early signs of immune complex deposition in susceptible individuals with family history.

Omega-3 fatty acids (EPA and DHA) promote the production of specialized pro-resolving mediators (SPMs)⁷⁷ specialized pro-resolving mediators (SPMs)
Lipid compounds derived from EPA and DHA that actively terminate inflammatory responses by promoting clearance of cellular debris and inhibiting pro-inflammatory cytokine production, compensating downstream for upstream impairments in receptor-mediated immune complex clearance.

Interactions

rs10800309 belongs to the second haplotype block of FCGR2A (block 1: rs4657039, rs6696854, rs10800309) distinct from the block containing rs1801274 (the well-studied H131R missense variant). The two blocks are independently inherited, meaning a person can carry the expression-reducing G allele at rs10800309 AND the affinity-reducing R131 allele at rs1801274 simultaneously — a combination that impairs both receptor quantity and receptor function simultaneously. This dual impairment creates the most pronounced deficit in immune complex clearance and may represent the highest-risk combination in the FCGR2A locus.

rs396991 (FCGR3A, F158V) encodes a separate but related Fc receptor expressed on NK cells and macrophages. Compound carriage of reduced-expression rs10800309 G alleles with reduced-function FCGR3A F158 alleles broadly depresses Fc-receptor-mediated immune surveillance across multiple cell lineages — an interaction relevant to both autoimmune clearance and antibody-dependent cellular responses to infections and biologics.